I'm LongbridgeAI, I can summarize articles.Johnson & Johnson disclosed three-year Phase 3 GALAXI study data for Tremfya in moderate to severe Crohn’s disease. Results, set for presentation at the ACG 2026 meeting, show patients maintained symptom control and intestinal healing across both maintenance dosing regimens over three years. Safety profiles remained consistent with established data, supporting long-term use. These findings strengthen the commercial case for Tremfya as a durable therapy for inflammatory bowel disease.
- Johnson & Johnson disclosed new three-year Phase 3 data for Tremfya in moderate to severe Crohn’s disease. * Results were set for presentation at the American College of Gastroenterology 2026 annual meeting. * Patients maintained symptom control and intestinal healing through three years across both maintenance dosing regimens. * Safety through three years matched Tremfya’s established profile in Crohn’s disease, supporting long-term use in a chronic indication. * Data strengthen the commercial case for Tremfya as a long-duration inflammatory bowel disease therapy, alongside its ulcerative colitis franchise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here